Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-02-2010 | Retinal Disorders

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

Authors: Thomas Ach, Alexandra E. Hoeh, Karen B. Schaal, Alexander F. Scheuerle, Stefan Dithmar

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2010

Abstract

Background

To evaluate prognostic factors of response to intravitreal bevacizumab therapy of macular edema (ME) due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).

Methods

Patients with ME due to CRVO (32 patients) or BRVO (38 patients) received intravitreal bevacizumab (2.5 mg/0.1 ml) at baseline, and every 6 to 8 weeks if OCT showed persistent or recurrent ME. Visual acuity (EDTRS), ophthalmic examination and OCT were performed at baseline and at all follow-up visits. Six to 8 weeks after first injection, baseline factors (visual acuity, central retinal thickness, age and gender) were analyzed retrospectively between patients with resolved ME (group 1) and persisting ME (group 2). At last visit, baseline factors of patients with resolved ME since first injection (group A), with recurrent ME since baseline (group B) and with persistent ME since baseline (group C) were compared.

Results

In CRVO patients, central retinal thickness (CRT) and patients’ age are prognostic predictors in bevacizumab therapy. Age of CRVO patients differed significantly between groups 1 and 2 after first injection, while CRT only showed a strong trend to thinner CRT. At last visit, age and CRT differed statistically significantly between groups A, B and C. In BRVO patients, none of the investigated factors revealed any prognostic value. In CRVO and BRVO patients, final CRT is correlated with the CRT after first injection.

Conclusion

CRT and age of patients have prognostic value in bevacizumab therapy of ME due to CRVO. CRVO patients who benefit from therapy are significantly younger and have a lower CRT at baseline than patients with persisting ME. In BRVO patients, no predictive factors for effectiveness of bevacizumab therapy could be observed.

Central Vein Occlusion Study Group (1993) Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group. Online J Curr Clin Trials Doc No 95

Berker N, Batman C (2008) Surgical treatment of central retinal vein occlusion. Acta Ophthalmol 86:245–252CrossRefPubMed

Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland. Ophthalmologe 104:290–294CrossRefPubMed

Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751–758PubMed

Klein ML, Finkelstein D (1989) Macular grid photocoagulation for macular edema in central retinal vein occlusion. Arch Ophthalmol 107:1297–1302PubMed

Badala F (2008) The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 19:234–238CrossRefPubMed

Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149CrossRefPubMed

Hoh AE, Schaal KB, Scheuerle A, Schutt F, Dithmar S (2008) OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion. Ophthalmologe 105:1121–1126CrossRefPubMed

Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Volker M, Holz FG, Bartz-Schmidt KU (2006) [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. Ophthalmologe 103:471–475CrossRefPubMed

10.

Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 27:1004–1012CrossRefPubMed

11.

Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425CrossRefPubMed

12.

Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S (2007) Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 104:285–289CrossRefPubMed

13.

Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284CrossRefPubMed

14.

The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491

15.

Chen JC, Klein ML, Watzke RC, Handelman IL, Robertson JE (1995) Natural course of perfused central retinal vein occlusion. Can J Ophthalmol 30:21–24PubMed

16.

Zhang H, Xia Y (2002) Analysis of visual prognosis and correlative factors in retinal vein occlusion. Zhonghua Yan Ke Za Zhi 38:98–102PubMed

17.

Esrick E, Subramanian ML, Heier JS, Devaiah AK, Topping TM, Frederick AR, Morley MG (2005) Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 139:653–657CrossRefPubMed

18.

Subramanian ML, Heier JS, Esrick E, Devaiah AK, Topping TM, Frederick AR, Morley MG (2006) Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging 37:462–467PubMed

19.

Sasahara M, Mikawa A, Tajiri K, Kojima H, Saito I (2006) Visual prognosis of branch retinal vein occlusion with macular edema. Nippon Ganka Gakkai Zasshi 110:293–299PubMed

20.

Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM (1996) Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 103:551–560PubMed

21.

Klein R, Moss SE, Meuer SM, Klein BE (2008) The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 126:513–518CrossRefPubMed

22.

Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK (2005) Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 140:256–261PubMed

23.

Noma H, Funatsu H, Mimura T, Hori S (2008) Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 18:1017–1019PubMed

24.

Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412–416CrossRefPubMed

25.

Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA (2007) Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27:426–431CrossRefPubMed

26.

Rath EZ, Frank RN, Shin DH, Kim C (1992) Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 99:509–514PubMed

27.

Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247CrossRefPubMed

28.

Lang GE, Handel A (1992) Clinical and fluorescein angiography changes in patients with central retinal vein occlusion. A unicenter study of 125 patients. Klin Monatsbl Augenheilkd 201:302–308CrossRefPubMed

Title: Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion
Authors: Thomas Ach
Alexandra E. Hoeh
Karen B. Schaal
Alexander F. Scheuerle
Stefan Dithmar
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2010
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-009-1167-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2010

The effect of interferon β-1a on optic neuritis relapse in patients with multiple sclerosis

Fever after intravitreal anti-VEGF injections

Intraocular pressure changes following Descemet’s stripping with endothelial keratoplasty

Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy

Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis

Effect of anterior chamber air bubble on prevention of experimental Staphylococcus epidermidis endophthalmitis